WELCOME TO
Leveraging the Synergistic Properties of Prodrugs and Its Self-forming Nanoparticles to Enhance Safety and Efficacy
NanoScrips
NanoScrips is developing multiple prodrugs and self-forming nanoparticles for multiple indications. The strategy is to increase the probability of success by selecting molecules with:
a) Broader therapeutic applicability,
b) Known safety and efficacy profile
We have selected two short-chain fatty acid (SCFAs) - butyric acid (BA), propionic acid (PA); one branched chain fatty acid (BCFA) - Valproic acid (VPA); one more biomolecule - Gamma Amino Butyric Acid (GABA); and Phenyl butyrate (PBA) which itself is a prodrug of phenylacetate.
However these molecules have major pharmacokinetic (PK) limitations including a shorter half-life, lower bioavailability and higher dose requirements which offer an opportunities to innovate.
NanoScrips' candidates synergistically combine the features of two proven strategies to enhance PK profile, safety, efficacy and reduce the burden on patients.
Release of active pharmaceutical agent (API) is triggered by endogenous enzymes.
Novelty: Designing a Compound Which is Both a Prodrug & a Nanoparticle.
Thus, Enhance Bioavailability, Half-life, Safety and Efficacy.
It is Not a Formulation.
Its The Prodrug Itself That Becomes a Nanoparticle.
Pipeline and Indications / Applications
NS-001
(Pro-BA-NP)
Butyric acid (BA) is a
A) Radiation sensitizer,
And has demonstrated efficacy in animal models of
B) NASH,
C) Ulcerative colitis,
D) Retinal neurodegeneration
(There is a Phase I SBIR / STTR pending grant from National Eye Institute (NEI) at National Institutes of Health (NIH)0 and
E) Diabetes.
NS-002
(Pro-PBA-NP)
Phenylbutyrate (PBA) is FDA approved for the treatment of hyperammonemia. However it has significant side effects, requires larger doses and frequent dosing as a result of lower half-life.
A) Therefore, NS-002 is a candidate for 505(b)2 regulatory track for hyperammonemia.
B) PBA eye drop has demonstrated efficacy in animal models of glaucoma.
Our nanoparticles have demonstrated longer residence time on cornea and release PBA over a long period of time.
NS-003
(Pro-VPA-NP)
Valproate (VPA) is FDA approved for the treatment of epilepsy / seizures. Its similar limitations as lower half-life, requires higher dose and frequent dosing, and causes significant side effects.
A) Therefore, NS-003 also is a candidate for 505(b)2 regulatory track for epilepsy.
B) Also, VPA was touted as a treatment option for Alzheimer's Disease.
However, VPA had negative results in Phase II clinical trial.
NS-003 resolves PK limitations (high dose requirement, shorter half-life, lower bioavailability) of VPA and its safety issues.
Hence, NS-003 is a suitable candidate for development for Alzheimer's Disease.
NS-004
(Pro-GABA-NP)
Gamma Amino Butyric acid (GABA) is neurotransmitter implicated in inducing sleep.
Hence, NS-004 is a candidate for development for insomnia and sleep disorders.
NS-005
(Pro-PA-NP)
Propionic acid (PA) has demonstrated efficacy in several disease conditions as butyric acid.
Differentiators and Superiorities of
NanoScrips' Prodrugs & Nanoparticles
- Longer Half-life Compared to the API
- Higher Bioavailability
- Enhanced Safety and Efficacy
- Lower Nanometer Size (40-70 nm)
- Uniform Sized Nanoparticles
- Stable in Room Temperature
- Higher Accumulation in Liver and Pancreatic Tissue When Administered by I.V. route.
- Higher payload (50-60%)
- Extended Release ( When Given Via Oral and Systemic Routes)
- Higher Tumor Tissue Penetration
- Efficacious at Lower Doses
- Longer Residence Time on GI Mucosa and Cornea
- Lower Dose and Drug Burden
- Safer than the API
Contact Us
Address
1520 Luna Rd, Suite 120, Carrollton, TX 75006
Email:
contact@nanoscrips.com